Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fluciclatide · 2 trials · 10 indications
Mean relative differences of Standardized uptake value (SUV) following intravenous administration of AH111585 (F18) Injection between the two PET imaging sessions.
Correlation of the Magnitude of \[18F\]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Full Analysis Set (FAS) subjects. Correlation strength was defined descriptively. 0.22 and 0.24 equals a weak positive correlation and 0.16 and 0.18 equals a negligible correlation. Three (3) of the 22 subjects did not have any αvβ3 integrin results. Ki-inp-Patlak is a graphical analysis technique based on the compartment model that uses linear regression to identify and analyze pharmacokinetics of tracers involving irreversible uptake.
Correlation of the Magnitude of \[18F\]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Full Analysis Set (FAS) subjects. Correlation strength was defined descriptively. The Logan plot is the counterpart of the Patlak plot for reversible radiotracers.
Correlation of the Magnitude of \[18F\]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Full Analysis Set (FAS) subjects. Correlation strength was defined descriptively. SUVw\_55 is the standard uptake value at 55 minutes post-injection, normalized to weight.
Correlation of the Magnitude of \[18F\]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively. Twelve (12) of the 22 subjects had renal cell carcinoma (RCC) the remaining subjects did not have RCC. SUVR\_55\_blood is the standard uptake value ratio (tumor-to-blood) at 55 minutes post-injection.
Correlation of the Magnitude of \[18F\]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively.
Correlation of the Magnitude of \[18F\]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively.
Correlation of the Magnitude of \[18F\]Fluciclatide Uptake and Retention by tumor tissue following intravenous administration of AH111585 (18F) Injection for the Renal Cell Carcinoma (RCC) subjects. Correlation strength was defined descriptively.
| Arm | Type | Description |
|---|---|---|
| Fluciclatide Injection | EXPERIMENTAL | Fluciclatide Injection |
| Fluciclatide Injection - (AH111585 (F18)) | EXPERIMENTAL | Using of the drug product named, AH111585 (F18) Injection. It's generic chemical name is Fluciclatide. |
| Name | Type | Description |
|---|---|---|
| Fluciclatide Injection | DRUG | Fluciclatide Injection (AH111585 (18F) Injection) |
| Fluciclatide Injection - (AH111585 (F18)) | DRUG | 18F labelled Cyclic RGD peptide PET agent for injection. |
Inclusion Criteria: * The subject has been diagnosed with at least one solid primary or metastatic tumor greater than 2.0 cm in diameter, including but not limited to NSCLC, RCC, GBM, melanoma, sarcoma, breast and H\&N cancers. * The subject has received clinical routine imaging diagnostic work-up ...
Fluciclatide is an investigational small molecule being studied for use in oncology, specifically in solid tumors and high-grade glioma. It is a PET imaging agent designed to detect tumors and angiogenesis. Fluciclatide is currently in Phase 2 clinical development and is not yet approved by the FDA.
Fluciclatide is a small molecule PET imaging agent that targets angiogenesis, the process of new blood vessel formation in tumors. It is designed to detect tumors and angiogenesis in conditions such as high-grade glioma, lung cancer, head and neck cancer, sarcoma, and melanoma. The specific molecular target is not disclosed.
Fluciclatide is being developed by GE HealthCare Technologies Inc., a company publicly traded under the ticker symbol GEHC. The drug is currently in Phase 2 clinical trials for oncology indications, including solid tumors and high-grade glioma.
Fluciclatide is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 2 trials have been completed, with a total enrollment of 70 participants across studies for solid tumors, high-grade glioma, and other cancer types.
Fluciclatide has been studied in two completed Phase 2 clinical trials. NCT00565721 assessed its ability to detect tumors and angiogenesis in conditions including high-grade glioma, lung cancer, head and neck cancer, sarcoma, and melanoma. NCT00918281 evaluated the reproducibility of 18F uptake in solid tumors and other cancers.
Yes, Fluciclatide is also known as [18F]AH-111585. In clinical trials, it is referred to as an (18F) injection for PET imaging. The drug is being investigated for its ability to detect tumors and angiogenesis in various cancer types, including solid tumors and high-grade glioma.